US2019388445A1PendingUtilityA1

Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation

33
Assignee: VAN BERGENHENEGOUWEN JEROENPriority: Mar 8, 2017Filed: Sep 6, 2019Published: Dec 26, 2019
Est. expiryMar 8, 2037(~10.6 yrs left)· nominal 20-yr term from priority
Inventors:Jeroen Van BergenhenegouwenJohan GarssenClaudia Traidl-HoffmannCaroline Schlumprecht
A61P 11/02A61K 9/0043A61K 9/0095A61K 31/702A23L 33/40A23L 33/125A61K 47/26A61K 31/733A23V 2002/00A23L 29/30A61P 31/16A61P 37/00
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants.

Claims

exact text as granted — not AI-modified
1 . A method of treating and/or preventing non-allergic rhinitis in a human subject, comprising administering to a subject in need thereof a composition comprising non-digestible oligosaccharides. 
     
     
         2 . The method according to  claim 1 , wherein the non-digestible oligosaccharides comprise galacto-oligosaccharides and/or fructo-oligosaccharides. 
     
     
         3 . The method according to  claim 2 , wherein the non-digestible oligosaccharides comprise galacto-oligosaccharides and fructo-oligosaccharides. 
     
     
         4 . The method according to  claim 1 , wherein the human subject has an age of 0 to 36 months. 
     
     
         5 . The method according to  claim 4 , wherein the human subject is an infant. 
     
     
         6 . The method according to  claim 1 , wherein the composition is a nutritional composition. 
     
     
         7 . The method according to  claim 6 , wherein the nutritional composition is an infant formula or follow on formula. 
     
     
         8 . The method according to  claim 1 , wherein the non-allergic rhinitis is a chronic non-allergic rhinitis. 
     
     
         9 . The method according to  claim 1 , wherein the non-allergic rhinitis is a non-infectious non-allergic rhinitis. 
     
     
         10 . The method according to  claim 1 , wherein the administering comprises directly contacting the composition with nasal epithelial cells. 
     
     
         11 . The method according to  claim 1 , wherein the human subject is exposed to environmental air pollutants. 
     
     
         12 . The method according to  claim 1 , wherein the composition does not comprise  Lactobacillus rhamnosus.

Join the waitlist — get patent alerts

Track US2019388445A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.